title: The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions.
abstract: OBJECTIVE
  This study sought to determine whether the duration of pretreatment with the adenosine diphosphate receptor antagonist ticlopidine prior to intracoronary stenting is associated with the incidence of procedure-related non-Q-wave myocardial infarctions (MIs).
  
  
  BACKGROUND
  Dual antiplatelet therapy with ticlopidine and aspirin is routinely used with stenting, although ticlopidine is commonly not begun until the day of the procedure. Periprocedural MIs are at least partially platelet-dependent events. As the maximal platelet inhibitory effects of this drug take 2 to 3 days to be realized, we hypothesized that longer treatment prior to stenting would be associated with lower rates of procedure-related MIs.
  
  
  METHODS
  We reviewed outcomes in 175 consecutive patients treated with ticlopidine prior to stenting at the Cleveland Clinic Foundation. Those patients with an elevation in creatine kinase above our laboratory normal (>210 IU/L) with > or =4% MB fraction on routine evaluation were defined as having a non-Q-wave MI. RESULTS. There were 28 patients (16%) who had a non-Q-wave MI. Longer duration of ticlopidine pretreatment was strongly associated with a lower incidence of procedure-related non-Q-wave MIs (duration of pretreatment <1 day, 29% had MI; 1 to 2 days, 14%; > or =3 days, 5%; chi-square for trend=9.6; p=0.002). Ticlopidine pretreatment of > or =3 days was associated with a significant reduction in the risk of non-Q-wave MI (unadjusted odds ratio 0.18, 95% confidence interval=0.04 to 0.78, p=0.01) compared with pretreatment of <3 days.
  
  
  CONCLUSIONS
  Among patients undergoing intracoronary stenting, beginning ticlopidine therapy several days prior to the procedure is associated with a reduced risk of procedural non-Q-wave MIs.
authors.affiliation: Department of Cardiology and Joseph J. Jacobs Center for Thrombosis and Vascular Biology, Cleveland Clinic Foundation, Ohio 44195, USA.
authors.forename: S R
authors.initials: SR
authors.lastname: Steinhubl
authors.forename: M S
authors.initials: MS
authors.lastname: Lauer
authors.forename: D P
authors.initials: DP
authors.lastname: Mukherjee
authors.forename: D J
authors.initials: DJ
authors.lastname: Moliterno
authors.forename: A M
authors.initials: AM
authors.lastname: Lincoff
authors.forename: S G
authors.initials: SG
authors.lastname: Ellis
authors.forename: E J
authors.initials: EJ
authors.lastname: Topol
mesh_terms: D019917:Blood Vessel Prosthesis Implantation / Q000009:adverse effects*; D003327:Coronary Disease / Q000601:surgery; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D016017:Odds Ratio; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011300:Preoperative Care; D011446:Prospective Studies; D012307:Risk Factors; D015607:Stents / Q000009:adverse effects*; D013988:Ticlopidine / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine